4.1B Inhibitors
4.1B Inhibitors comprise a diverse array of chemical compounds that influence the functional activity of 4.1B through various biochemical pathways. Staurosporine and Chelerythrine, both potent kinase inhibitors, reduce the phosphorylation of proteins that may interact with 4.1B, potentially inhibiting its role in maintaining cell shape and stability. Similarly, Bisindolylmaleimide I targets PKC, a kinase that phosphorylates substrates interacting with 4.1B, thus possibly affecting its ability to support cell integrity. The actin cytoskeleton, which is integral to 4.1B's function, is disrupted by Cytochalasin D and Latrunculin A, both actin polymerization inhibitors. This disruption hinders 4.1B's scaffolding ability, impacting cell morphology and signal transduction. Furthermore, ML-7 and Blebbistatin, by inhibiting MLCK and myosin II ATPase respectively, reduce cytoskeletal tension and contractility, thereby indirectly inhibiting 4.1B's structural support to the plasma membrane.
Calyculin A, through the inhibition of protein phosphatases PP1 and PP2A, leads to a hyperphosphorylated state within the cell, potentially disturbing 4.1B's interaction with cytoskeletal elements. Y-27632, a ROCK inhibitor, and W-7, a calmodulin antagonist, alter the dynamics of the actin cytoskeleton and calcium-calmodulin-dependent processes, respectively, which are crucial for the anchoring function of 4.1B. The precise mechanisms by which these inhibitors act, whether by destabilizing the direct physical structure that 4.1B contributes to or by altering the signaling pathways in which 4.1B is implicated, demonstrate the intricate balance of cellular processes that 4.1B helps to regulate. Collectively, these inhibitors, by targeting specific pathways and enzymes, reveal the multi-faceted roles of 4.1B in cytoskeletal organization, cellular morphology, and possibly signaling, highlighting the complex interplay of structural and functional dynamics within the cell.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a potent inhibitor of protein kinases. By inhibiting a broad spectrum of kinases, it could suppress the phosphorylation events required for the scaffolding function of 4.1B, which is critical for maintaining cell shape and possibly for signal transduction relevant to cell adhesion processes. | ||||||
Calyculin A | 101932-71-2 | sc-24000 sc-24000A | 10 µg 100 µg | $163.00 $800.00 | 59 | |
Calyculin A is an inhibitor of protein phosphatases 1 (PP1) and 2A (PP2A). Since PP1 and PP2A regulate the phosphorylation status of many proteins, their inhibition can lead to hyperphosphorylation, which in turn may inhibit the interaction of 4.1B with its binding partners in the cytoskeleton, thereby disrupting cytoskeletal organization and related signaling. | ||||||
Cytochalasin D | 22144-77-0 | sc-201442 sc-201442A | 1 mg 5 mg | $165.00 $486.00 | 64 | |
Cytochalasin D disrupts actin filaments. Since 4.1B is associated with the actin cytoskeleton, the depolymerization of actin filaments by Cytochalasin D could inhibit 4.1B's ability to maintain cell shape and stability, thereby inhibiting its functional activity. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $105.00 $242.00 | 36 | |
Bisindolylmaleimide I is a specific inhibitor of Protein Kinase C (PKC). Given that PKC is involved in the phosphorylation of proteins that interact with 4.1B, inhibition of PKC can lead to a reduction in the phosphorylation-dependent conformational changes and interactions of 4.1B with other cytoskeletal elements, thereby inhibiting its function. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632 is an inhibitor of the Rho-associated protein kinase (ROCK). As ROCK is involved in actin cytoskeleton organization, its inhibition can lead to changes in cell shape and motility. Since 4.1B is associated with the cytoskeleton, the inhibition of ROCK could indirectly inhibit the structural role that 4.1B plays in cell morphology and motility. | ||||||
ML-7 hydrochloride | 110448-33-4 | sc-200557 sc-200557A | 10 mg 50 mg | $91.00 $267.00 | 13 | |
ML-7 is an inhibitor of myosin light chain kinase (MLCK). MLCK plays a role in controlling the phosphorylation of myosin light chains, which is crucial for actin-myosin contractility. Inhibition of MLCK by ML-7 may reduce tension within the cytoskeleton, which could affect the mechanical stability that 4.1B confers to the plasma membrane and its associated structures. | ||||||
(±)-Blebbistatin | 674289-55-5 | sc-203532B sc-203532 sc-203532A sc-203532C sc-203532D | 5 mg 10 mg 25 mg 50 mg 100 mg | $183.00 $313.00 $464.00 $942.00 $1723.00 | 7 | |
Blebbistatin is an inhibitor of myosin II ATPase activity. By inhibiting myosin II, Blebbistatin can affect cell contractility and shape, which depend on the actomyosin network. As 4.1B is linked to the actin cytoskeleton, altering the dynamics of myosin II can indirectly inhibit 4.1B's role in maintaining cell integrity and morphology. | ||||||
W-7 | 61714-27-0 | sc-201501 sc-201501A sc-201501B | 50 mg 100 mg 1 g | $166.00 $306.00 $1675.00 | 18 | |
W-7 is a calmodulin antagonist that inhibits calcium-calmodulin-dependent processes. Since 4.1B potentially interacts with proteins that are regulated by calcium-calmodulin signaling, such as spectrin, the inhibition of this pathway may alter the stability and function of the spectrin-actin network and indirectly inhibit 4.1B's associated functional activities. | ||||||
Latrunculin A, Latrunculia magnifica | 76343-93-6 | sc-202691 sc-202691B | 100 µg 500 µg | $265.00 $815.00 | 36 | |
Latrunculin A binds to actin monomers and prevents their polymerization. The disruption of actin filaments can inhibit the anchoring function of 4.1B, which is crucial for its role in maintaining cell shape and possibly in signal transduction processes linked to the cytoskeleton. | ||||||
Chelerythrine | 34316-15-9 | sc-507380 | 100 mg | $540.00 | ||
Chelerythrine is an inhibitor of PKC. Since PKC phosphorylates multiple substrates that can interact with 4.1B, the inhibition of PKC by Chelerythrine may reduce the functional activity of 4.1B by altering its phosphorylation state and its interactions with other cytoskeletal proteins, thereby affecting cellular structure and signaling. | ||||||